0001209191-14-002558.txt : 20140109
0001209191-14-002558.hdr.sgml : 20140109
20140109142600
ACCESSION NUMBER: 0001209191-14-002558
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140106
FILED AS OF DATE: 20140109
DATE AS OF CHANGE: 20140109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EnteroMedics Inc
CENTRAL INDEX KEY: 0001371217
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2800 Patton Rd
CITY: St Paul
STATE: MN
ZIP: 55113
MAIL ADDRESS:
STREET 1: 2800 Patton Rd
CITY: St Paul
STATE: MN
ZIP: 55113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EVNIN LUKE
CENTRAL INDEX KEY: 0001134657
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33818
FILM NUMBER: 14518426
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-01-06
0
0001371217
EnteroMedics Inc
ETRM
0001134657
EVNIN LUKE
C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR
BOSTON
MA
02116
1
0
0
0
Common Stock
2014-01-06
4
S
0
81720
2.50
D
1588033
I
See footnote
Common Stock
2014-01-07
4
S
0
190334
2.50
D
1397699
I
See footnote
Common Stock
2014-01-08
4
S
0
284531
2.50
D
1113168
I
See footnote
The shares were sold as follows: 68,003 by MPM BioVentures III-QP, L.P. ("BV III QP"), 4,572 by MPM BioVentures III, L.P. ("BV III"), 2,054 by MPM BioVentures III Parallel Fund, L.P. ("BV III PF"), 5,747 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV III KG") and 1,344 by MPM Asset Management Investors 2002 BVIII LLC ("AM LLC").
The shares are held as follows: 1,321,479 by by BV III QP, 88,852 by BV III, 39,924 by BV III PF, 111,670 by BV III KG and 26,108 by AM LLC. MPM BioVentures III GP, L.P. ("BVIII GP") and MPM BioVentures III LLC ("BVIII LLC") are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC.
The shares were sold as follows: 158,386 by by BV III QP, 10,650 by BV III, 4,785 by BV III PF, 13,384 by BV III KG and 3,129 by AM LLC.
The shares are held as follows: 1,163,093 by by BV III QP, 78,202 by BV III, 35,139 by BV III PF, 98,286 by BV III KG and 22,979 by AM LLC. BVIII GP and BVIII LLC are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC.
The shares were sold as follows: 236,772 by by BV III QP, 15,919 by BV III, 7,154 by BV III PF, 20,008 by BV III KG and 4,678 by AM LLC.
The price in Column 4 is a weighted average sale price. The prices actually ranged from $2.50 to $2.51. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The shares are held as follows: 926,321 by by BV III QP, 62,283 by BV III, 27,985 by BV III PF, 78,278 by BV III KG and 18,301 by AM LLC. BVIII GP and BVIII LLC are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC.
/s/ Luke Evnin
2014-01-09